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ABSTRACT    
Objective: We tested the ability of a type 1 diabetes (T1D) genetic risk score (GRS) to 
predict progression of islet autoimmunity and T1D in at-risk individuals.  
Research Design and Methods: We studied the 1,244 TrialNet Pathway to Prevention 
study participants (non-diabetic, autoantibody-positive (Ab+) relatives of patients) who 
were genotyped with Illumina ImmunoChip (median [range] age at initial autoantibody 
determination=11.1 years [1.2-51.8], 48% male, 80.5% non-Hispanic White; median 
follow-up=5.4 years). Of 291 participants with single Ab+ at screening, 157 converted to 
multiple Ab+, and 55 developed diabetes. Of 953 participants with multiple Ab+ at 
screening, 419 developed diabetes. We calculated the T1D GRS from 30 T1D-associated 
SNPs. We used multivariable Cox regression models, time-dependent ROC curves and 
AUC measures to evaluate prognostic utility of T1D GRS, age, sex, Diabetes Prevention 
Trial-1 Risk Score (DPTRS), Ab+ number or type, HLA DR3/DR4-DQ8 status, and 
race/ethnicity. We used recursive partitioning analyses to identify cut-points in continuous 
variables.  
Results: Higher T1D GRS significantly increased the rate of progression to T1D adjusting 
for DPTRS, age, Ab+ number, sex, and ethnicity (HR=1.29 for a 0.05 increase, 
95%CI=1.06-1.6, P=0.011). Progression to T1D was best predicted by a combined model 
with GRS, Ab+ number, DPTRS and age (7-year time-integrated AUC=0.79, 5-year 
AUC=0.73). Higher GRS was significantly associated with increased progression rate 
from single to multiple Ab+ after adjusting for age, Ab+ type, ethnicity, and sex 
(GRS>0.295, HR=2.27, 95%CI=1.47-3.51, P=0.0002).  
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Conclusion: The T1D GRS independently predicts progression to T1D, and improves 
prediction along T1D stages in Ab+ relatives.  
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Early identification of individuals at risk for type 1 diabetes (T1D) allows study of 
the biology of the preclinical stages of T1D, and inclusion of those at highest T1D risk in 
T1D monitoring and prevention trials. Current prediction models for T1D use immunologic 
and metabolic markers but these change during disease progression and reflect 
advanced stages in the autoimmune process (1-8) whereas genetic predictors are time-
independent and may be assessed only once at study entry. T1D has a significant 
heritable risk as evidenced by studies of monozygotic twins demonstrating rates of 
concordance >50% for disease, higher with younger age at diagnosis of the index twin 
(9; 10). Approximately 50% of this heritability is attributable to the HLA region (11), with 
another >50 loci making smaller contributions to disease risk  (reviewed in (12-14)). 
Recently, Oram et al. developed and validated a T1D genetic risk score (T1D GRS) that 
incorporates HLA and non-HLA T1D-associated SNPs (15) and was discriminative of T1D 
from type 2 diabetes, monogenic diabetes and controls (16). In this study, we tested the 
prognostic utility of the T1D GRS for differentiating rates of progression of islet 
autoimmunity and development of clinical T1D in autoantibody-positive relatives of 
individuals with T1D.  
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RESEARCH DESIGN AND METHODS 
Participants 
TrialNet is a NIH-funded international network that aims to prevent T1D (17). 
TrialNet Pathway to Prevention (PTP) is an observational study that prospectively follows 
at-risk first or second-degree relatives of patients with T1D for development of islet 
autoimmunity and clinical T1D (18). This study included TrialNet PTP participants who 
had ≥1 positive persistently detectable islet autoantibody and had been genotyped using 
the Illumina ImmunoChip (n=1,244). Study participants gave informed consent and the 
study was approved by ethics committees at each site. 
Procedures 
Participants were initially screened for autoantibodies to glutamic acid 
decarboxylase (GAD65), insulin (microinsulin antibody assay, mIAA) and insulinoma-
associated antigen 2 (IA-2A). If any of these were positive, autoantibodies to zinc 
transporter 8 (ZnT8) and islet cell antibodies (ICA) were tested. Participants were 
monitored with autoantibody testing, hemoglobin A1c (HbA1c) and oral glucose tolerance 
test (OGTT) at 6- or 12-month intervals depending on estimated risk (19). T1D was 
diagnosed in participants with: i) symptomatic hyperglycemia, defined as fasting plasma 
glucose ≥7.0 mmol/L, 2-hour plasma glucose after 75g oral glucose ≥11.1 mmol/L, a 
random plasma glucose ≥11.1 mmol/L or a HbA1C ≥ 6.5%; or ii) asymptomatic 
hyperglycemia documented on two separate occasions. Islet autoantibody (18) and C-
peptide (20) assays have been previously described. HLA genotyping was performed as 
previously described (21). Illumina ImmunoChip genotyping was performed at the Center 
for Public Health Genomics, University of Virginia. The Diabetes Prevention Trial-1 (DPT-
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1) Risk Score is a diabetes risk score derived from ICA-positive individuals and validated 
in TrialNet that combines BMI, age, glucose, and C-peptide (2; 22). We stratified our 
analysis by a metabolic DPT-1 Risk Score of ≤7 or >7 based on previous work (23).  
T1D GRS 
The T1D GRS was calculated from 30 variants known to be associated with T1D 
(Supplementary Table S2), ranked and weighed by published odds ratios as previously 
described (15). We drew ORs for each SNP from the largest available meta-analysis 
study that used T1Dbase (https://www.t1dbase.org/page/Welcome/display). Twenty-nine 
of these variants were directly genotyped whereas rs11755527 was imputed 
using IMPUTE2 (r2=0.99997). rs2187668 and rs7454108 were used to determine HLA 
DR haplotype (24).  The T1D GRS threshold that was previously shown to optimally 
discriminate T1D from T2D was 0.280 (15). T1D GRS percentiles in a reference T1D 
population (25) are provided to allow comparisons between different genetic scores. The 
same methods were used to calculate a 10-SNP score using the top 10 T1D-associated 
SNPs (Supplementary Table S2), which account for most of the genetic risk.  We 
assessed the predictive power of both the 10 SNP and 30 SNP scores. 
Statistical Analyses 
We used summary statistics and graphical analyses to assess the distributions and 
characteristics of the clinical and metabolic measures as well as the T1D GRS, overall 
and by subgroup. Comparisons between subgroups were made using primarily 
nonparametric approaches, e.g. Wilcoxon rank sum or Kruskal-Wallis tests, and the chi-
square or Fisher exact tests, as appropriate.  
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Kaplan-Meier methods were used to evaluate the time-to-event distributions for 
time to progression to T1D and time from single to multiple autoantibody positivity overall 
and in subgroups (see Supplementary Table S3 for definitions). Cox proportional hazards 
models were used to test the prognostic influence of these measures on these outcomes 
in univariate and multivariable settings. Models were adjusted for age, sex, and 
race/ethnicity. For models of time to conversion from single to multiple autoantibodies, 
we also adjusted for autoantibody type (i.e. GAD65, insulin or IA-2A). For time-to-T1D 
models, we additionally adjusted for DPT-1 Risk Score and the number of positive 
autoantibodies present at screening. T1D GRS, age, and DPT-1 Risk Score were each 
evaluated as continuous and dichotomized factors. We assessed whether T1D GRS 
added predictive power independently over HLA DR3/DR4-DQ8 status by including 
DR3/DR4-DQ8 in initial multivariate analyses; the HLA DR3/DR4-DQ8 variable was then 
removed from the final models due to the overlap between the two variables (i.e., HLA 
DR3/DR4-DQ8 is included in the T1D GRS) causing collinearity. Recursive partitioning 
analyses (risk-stratification method based on classification and regression trees) were 
used to identify variables and associated cut-points that best differentiated outcome-
specific risk (rpart package in R) (26). To obtain stable hazard ratio (HR) estimates 
reflecting meaningful unit changes in the continuous 30-SNP T1D GRS measure, we 
multiplied this measure by a constant (x20) when included as a continuous factor in 
models. All reported HRs for continuous T1D GRS measures reflect this multiplier and 
reflect HRs associated with an increase of 0.05 in the T1D GRS.  
The predictive accuracy of models for time to progression to multiple 
autoantibodies and to T1D was evaluated for T1D GRS (or HLA), islet autoantibody 
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number, age, and DPT-1 Risk Score using time-dependent AUC analyses (survAUC in 
R). Time-integrated AUC measures were calculated for each model in addition to year-
specific AUCs on subjects with complete data for the multivariable models, consistent 
with standard AUC goodness-of-fit measures. In addition, to evaluate if GRS added more 
to our prognostic models than HLA, we directly compared the GRS vs. HLA models as 
well as when combined with clinical factors (DPT-1 Risk Score, age, autoantibody 
number). Time-integrated AUC estimates were limited to 7 years given that the 3rd quartile 
for follow-up in event-free participants in the overall cohort was just over 7 years. 
Predictive accuracy between models was compared at major time points and reflect 
comparisons of estimated 5-year AUCs unless stated otherwise (timeROC package in R).  
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RESULTS 
Characteristics of TrialNet participants in this study (N=1,244) are presented in 
Supplementary Table S4. The median age at autoantibody determination was 11.1 years 
(range 1.2-51.8), 48% were male, 81% non-Hispanic White, and 90% first-degree 
relatives of a patient with T1D. The estimated median follow-up was 5.4 years 
[95%CI=5.0-5.8 years]. Of the 291 participants positive for a single antibody, 157 
progressed to multiple autoantibody positivity and 55 developed T1D. Of the 953 
participants who had multiple antibodies when initially screened, 419 developed T1D.  
Overall, the 30-SNP T1D GRS ranged from 0.138 to 0.341 (median=0.272, 
corresponding to the 38th-39th percentiles in the reference T1D population (25)). The 
median T1D GRS for single and multiple autoantibody positive subjects were 0.266 (30th 
percentile; range=0.138-0.341) and 0.274 (41st percentile; range=0.169-0.328), 
respectively.  
 
The T1D GRS is an independent predictor of clinical T1D in islet autoantibody positive 
relatives  
The T1D GRS was a significant predictor of risk and rate of progression to T1D in 
continuous univariate analysis (HR=1.7, 95% CI: 1.43-2.0; P<0.0001) as well as after 
adjustment for other risk factors (Supplementary Table S5). Of note, with inclusion of the 
T1D GRS in the multivariable model, HLA DR3/DR4-DQ8 was no longer significant 
(HR=1.06, 95% CI: 0.79-1.41, P=0.71, data not shown). The best predictive model of 
progression to T1D, with a 7-year time-integrated AUC of 0.794, included GRS, the 
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metabolic DPT-1 Risk Score, age at autoantibody determination and number of positive 
autoantibodies (Supplementary Table S5). The GRS remained a significant predictor in 
this model (HR=1.29, 95%CI: 1.06-1.56; P=0.009). Since we observed a significant 
interaction between T1D GRS and DPT-1 Risk Score (P=0.001) as well as between GRS 
and autoantibody number (P=0.001), next we also analyzed models of progression to 
T1D stratified by these features.  
Interaction and stratified analyses revealed that GRS is best able to further 
differentiate T1D risk in those participants with a baseline metabolic DPT-1 Risk Score 
≤7.0 (N=716, which represents 63% of 1136 participants with DPT-1 Risk Score data 
available at baseline) (HR=1.66, 95%CI:1.18-2.34, P=0.003) even after adjusting for age, 
autoantibody number, sex, ethnicity, and DPT-1 Risk Score (Supplementary Table S5b). 
Although those with a DPT-1 Risk Score >7 had a higher T1D GRS than those with DPT-
1 Risk Score ≤7 (0.274 (0.026) vs. 0.268 (0.028), P=0.002), the GRS did not further 
stratify the risk of T1D in participants who had already developed metabolic abnormalities, 
as reflected by a DPT-1 Risk Score>7.0 (HR=1.07, 95%CI=0.81-1.41, P=0.64).  
Since ICA and GAD65 autoantibodies may overlap [NEED REF BUT WE’RE AT 
MAX ALLOWED], we performed sensitivity analyses with the 167 (out of 1244) subjects 
who were only positive for ICA and GAD65 in this cohort and observed that their 
classification as positive for one versus two autoantibodies yielded similar results and 
consistent estimates.  
Multivariable recursive partitioning models identified variable cut-points and five 
risk clusters (Figure 1 and Supplementary Figure 1). The optimal cut-point for GRS in 
relation to time to progression to T1D was 0.250. DPT-1 Risk Score >7 identified the 
Comment	[MOU1]:	Technically ICA may include other 
antibodies, not just GAD-Ab 
Formatted:	Highlight
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highest risk group, while in those with DPT-1 Risk Score ≤7, the risk of T1D could be 
further stratified according to autoantibody number and T1D GRS.  To assess the 
improvement of T1D prediction when including T1D GRS with established predictors, we 
calculated time-dependent ROC curves integrated across all time points (iAUC) and 
standard ROC curves for the 2- and 5-year time point. For the overall at-risk cohort with 
complete data on these factors (N=1106, 415 events), the iAUCs were 0.57 for T1D GRS, 
0.53 for HLA, 0.59 for autoantibody number, 0.59 for age, and 0.774 for DPT-1 Risk 
Score. The iAUC for the final composite risk model (i.e. T1D GRS, metabolic DPT-1 Risk 
Score, age, and autoantibody number) was 0.794. Given that we identified that GRS has 
the most prognostic utility in participants with DPT-1 Risk Scores ≤7, we also evaluated 
the time-dependent ROC and AUC measures in those with complete data on these 
factors (N=696, 132 T1D events). In this subset, we found similar patterns of iAUC for 
these factors. We observed that the model with GRS combined with the “clinical” variables 
(i.e., DPT-1 Risk Score, age and autoantibody number) had significantly better prediction 
accuracy than the model with HLA combined with the clinical variables, although this was 
significant at earlier time points (i.e. ROC and AUC estimates for up to 3 years). For 
example, the 2-year AUC for the clinical+HLA model was 0.78 vs. 0.82 for the 
clinical+GRS model (p<0.0001; Figure 2).  Similarly, we observed that, in the participants 
with lower metabolic risk, the T1D prediction model that combined GRS in addition to the 
clinical variables DPT-1 Risk Score, age and autoantibody number performed significantly 
better than HLA DR3/DR4-DQ8 in addition to the clinical variables (iAUC: 0.60 vs. 0.53; 
p=0.007).  
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The T1D GRS is an independent predictor of progression from multiple islet autoantibody 
positivity to T1D 
There were 953 participants who were identified as having multiple autoantibody 
positivity at screening and 157 additional participants who developed multiple positive 
autoantibodies during follow-up, for a total of 1,110 multiple autoantibody positive 
participants in our cohort. After adjusting for age and DPT-1 Risk Score, the T1D GRS 
was a significant independent prognostic factor for time to progression to T1D as a 
continuous (P=0.015) and as a dichotomized variable (cut-point=0.250, P=0.017, 
Supplementary Table S6). Among multiple autoantibody positive participants with lower 
metabolic DPT-1 Risk Score, high T1D GRS was a significant factor in multivariable 
analysis (T1D GRS≥0.250, HR=2.07, 95%CI=1.21-3.55, P=0.008) (Supplementary Table 
S6b). Five-year T1D-free rate estimates were 89% for those with a low T1D GRS (<0.250) 
versus 77% in participants with high T1D GRS (≥0.250). The risk of progressing from 
multiple islet autoantibody positivity to T1D could be stratified by the composite grouping 
of DPT-1 Risk Score, age and T1D GRS (Figure 3). Time-to-event ROC and AUC 
analyses demonstrated that the addition of GRS to the model with age and DPT-1 Risk 
Score improved the prediction model for T1D in a similar manner to that seen in all 
autoantibody positive participants with DPT-1 Risk Scores ≤7 (2-year AUC: 
clinical+HLA=0.68 vs. clinical+GRS=0.73; p<0.0001). Interestingly, the GRS improved 
the prediction afforded by HLA DR3/DR4-DQ8 alone (iAUC: 0.647 vs. 0.564, respectively; 
p=0.006).  
 
The T1D GRS is an independent predictor of progression of islet autoimmunity  
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In our cohort, 157 of the 291 single autoantibody positive participants progressed 
to multiple islet autoantibody positivity. Elevated T1D GRS was associated with 
progression from singe to multiple autoantibody positivity, where an increase of 0.050 
(e.g. from 0.225 to 0.275) significantly increased risk by 50% (HR=1.49, 95%CI=1.1-2.05, 
P=0.015) after adjustment for age, sex, ethnicity, and autoantibody type (Supplementary 
Table S7).  
Recursive partitioning identified 0.295 (69-70th percentiles) as the optimal cut-point 
to discriminate individuals with the highest rate of progression from single to multiple 
autoantibody positivity. Single autoantibody positive participants whose T1D GRS 
exceeded 0.295 had above two times higher risk of autoantibody progression (HR=2.27, 
95%CI=1.47-3.51, P=0.0002) even adjusting for age, autoantibody type, sex, and 
ethnicity.    
We observed a potential interaction between T1D GRS and age at first 
autoantibody determination (P=0.052). In participants younger than 35 years (n=229), 
after adjusting for age, sex, ethnicity, and autoantibody type, T1D GRS was a significant 
predictor of progression to multiple Ab+, both as a continuous (HR=1.65, 95%CI=1.15-
2.37, P=0.0065) and dichotomous variable, with a cut-point of 0.295 (HR=2.57, 
95%CI=1.6-4.13, P=0.0001) but also 0.250 (HR=1.68, 95%CI=1.07-2.64, P=0.023). On 
the other hand, in older participants (≥35 years of age when classified as single 
autoantibody positive), who were at much lesser risk of T1D overall, the T1D GRS did not 
significantly inform the risk and prognosis for progression to multiple autoantibody 
positivity after adjusting for autoantibody type and sex (age was not significant and thus 
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was excluded from the model) although the numbers were relatively smaller (n=62, 
HR=0.86, 95%CI=0.25-2.96, P=0.81) (Figure 4).   
In time-dependent ROC analysis, the T1D GRS alone delivered an iAUC of 0.55 
compared to 0.53, 0.52 and 0.53 for age, autoantibody type and HLA DR3/DR4-DQ8 
heterozygosity, respectively. The iAUC of a multivariable model that combined age, 
autoantibody type and T1D GRS was 0.581.  
 
A reduced 10-SNP T1D GRS performed similarly to the T1D GRS in predicting 
islet autoimmunity progression and T1D 
We evaluated the performance of a T1D GRS based on the top 10 SNPs (listed in (15)) 
(T1D GRS-10), using the same analytic approach as for the 30-SNP measure. In 
multivariable analysis, the T1D GRS-10 predicted progression to T1D in all subjects 
(HR=1.16 for each increase by 0.10 in score, 95%CI=1.03-1.31, P=0.014) and in the 
subgroup of multiple positive autoantibody subjects (HR=1.15, 95%CI= 1.02-1.30, 
P=0.024).  Similarly to the 30 SNP score, the 10-SNP GRS was only a significant factor 
in those with the metabolic DPT-1 Risk Score <7 (P=0.0026). T1D GRS-10 also predicted 
progression from single to multiple autoantibody positivity after adjusting for age, sex, 
ethnicity, and autoantibody type (HR=1.26 for a 0.1 increase in T1D GRS-10, 
95%CI=1.03-1.55, P=0.026). The overall predictive power of GRS-10 was similar to that 
of GRS-30 (iAUC=0.575).  
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CONCLUSIONS 
We studied 1,244 initially non-diabetic, islet autoantibody positive relatives of 
patients with T1D and demonstrated that the T1D GRS is an independent predictor of 
progression of islet autoimmunity and development of clinical T1D. The T1D GRS 
improved current prediction models by stratifying risk among individuals who were either 
single or multiple autoantibody positive. We demonstrated that the combined modeling of 
the T1D GRS, which includes HLA and non-HLA factors, in addition to autoantibody and 
metabolic data offers better prediction of T1D in at-risk relatives. This approach could 
increase our ability to predict T1D in relatives of patients, as well as screen and select 
participants for natural history studies and intervention trials.  
This study adds to the recent expanding literature on the applicability of genetic 
information in the prediction of T1D. The T1D GRS used in the present study was 
originally developed and validated to distinguish T1D and type 2 diabetes in the Wellcome 
Trust Case Control Consortium (n=3,887) and in a cohort defined by insulin insufficiency 
(15). The score was also able to discriminate T1D and maturity-onset diabetes in the 
young (MODY) and, in neonatal diabetes, individuals with monogenic neonatal diabetes 
(16). Our present findings extend the use of the T1D GRS to prediction of T1D in relatives 
at risk. There have been previous attempts to develop genetic scores that integrate 
genetic information to improve the prediction of T1D (reviewed in (27)). In particular, it 
was shown that the combination of HLA and non-HLA genetic factors increases the power 
of the T1D predictive model (28-31). Winkler et al (29) developed a genetic score using 
logistic regression and Bayesian feature selection of T1D Genetic Consortium to define 
a set of 10 SNPS, including HLA, that identified risk of T1D in first-degree relatives from 
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the BABYDIAB study. Our score, although generated from a log-additive model, contains 
very similar genetic information so it is not surprising that the results are consistent. A key 
additional benefit of our T1D GRS is the inclusion of SNPs tagging other significant HLA 
risk alleles, e.g. HLA DRB1*15, DRB1*57 and A24. Specifically, DRB1*15:01 (linked to 
DQB1*06:02) is common in Caucasians and confers strong genetic protection against 
T1D (21). A score generated by merging the Winkler (29; 30) and Oram (15) scores has 
recently been proposed to identify newborns from the general population who will develop 
islet autoimmunity and T1D. In this study, Bonifacio et al. (32) demonstrated that, even in 
a subset of individuals with high risk HLA genotypes from the TEDDY study, a T1D 
genetic score predicted development of autoantibodies. While different characteristics in 
each cohort (e.g. age, background risk of T1D, proportion of individuals with a relative 
with T1D) may require adaptations of the T1D GRS, the concept of combining genetic 
information into a single factor will greatly improve its utility for prediction and trial design. 
By virtue of being a number, the T1D GRS facilitates incorporation of complex genetic 
information into prediction models. Importantly, selecting appropriate cut-points will 
optimize the use of the T1D GRS for different goals.  
The T1D GRS significantly added predictive power to the current variables used 
to stratify T1D risk in the TrialNet PTP study. The measurement of autoantibodies and 
differences in risk associated with autoantibody positivity are well described (33) as well 
as age and metabolic data (34-36). The fact that the T1D GRS was not a predictor in 
those with DPT-1 Risk Score >7 demonstrates that, when metabolic abnormalities 
develop, measures that evaluate these directly become most predictive and, 
consequently, the role of genetics in risk assessment diminishes. However, the majority 
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of individuals entering TrialNet PTP have a low DPT-1 Risk Score; in this group, the 
addition of T1D GRS to the currently established predictors (i.e. age, autoantibody 
number, DPT-1 Risk Score) can best add predictive power and assist in stratification for 
prevention trials. In the present study, multivariate modeling of autoantibody status, DPT-
1 Risk Score, age and additional demographic factors still leaves the T1D GRS as a 
significant independent predictor of progression. This observation supports the 
assessment of all of these features, either in a combined model or a sequential approach, 
at entry to the TrialNet PTP and other similar studies. Previous studies have shown 
conflicting results on the ability of genetic factors, age, autoantibody and metabolic data 
to predict T1D (36; 37). Some of the differences in the role of genetics could be due to 
the challenges to capture genetic information; an advantage of the T1D GRS is that it 
includes SNPs tagging other significant HLA risk alleles, e.g. HLA DRB1*15, DRB1*57 
and A24, in addition to non-HLA SNPs. Supporting this notion, in the present study, the 
T1D GRS was superior to HLA DR3/DR4-DQ8 alone to predict progression to T1D. Since 
the T1D GRS further stratified T1D risk beyond that associated with autoantibody number 
in individuals with low DPT-1 Risk Score, it is plausible that applying the T1D GRS earlier 
in life would allow discrimination of the individuals who will develop a high DPT-1 Risk 
Score and T1D. 
The unique longitudinal follow up and monitoring of the TrialNet PTP study also 
allowed us to further investigate the contribution of the GRS to pre-clinical stages of T1D. 
Progression from single to multiple autoantibody positivity was independently predicted 
by the T1D GRS in participants younger than 35 years of age. Because our cohort 
included a relatively limited number of individuals ≥35 years old, larger studies will be 
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required to better assess the applicability of the GRS in this age group. We had previously 
observed the protective effect of age on progression to T1D in at-risk adults with a 
threshold of 35 years of age (38) and the influence of age on the effect of another genetic 
factor, namely type 2 diabetes-associated TCF7L2 variants on T1D progression (39). 
Interestingly, despite having been originally discovered in studies in childhood diabetes, 
the T1D GRS was able to identify more adult than childhood T1D cases in a recent study 
of T1D in UK Biobank (40). These results and those from the present study suggest that 
the genetic factors that regulate the progression of islet autoimmunity may slightly differ 
by age and further support the emerging notion that age is a key factor in the 
heterogeneity of T1D pathogenesis. The importance of age in progression through T1D 
stages is also highlighted by its significant and strong influence in the multivariable 
models even after adjustment for DPT-1 Risk Score, which includes age as well.  
We tested the predictive power of a restricted set of the top 10 SNPs from our 
score (15), which proved to contain the vast majority of predictive power in the T1D GRS. 
This is unsurprising due to the high weights of HLA and the top SNPs in the score. These 
results may be relevant to large scale studies where the cost of the T1D GRS per 
individual may be important.  
The study limitations include that it evaluated the performance of T1D GRS only in 
autoantibody-positive relatives of people with T1D, although recent data (32) suggest that 
the T1D GRS will be a significant predictor in general population cohorts as well. We 
tested the T1D GRS and derived score cutoffs within the 1,244 TrialNet participants who 
had ImmunoChip data; we anticipate that expanding SNP analysis to the whole cohort 
will validate the current findings. Similarly, TrialNet is a cohort of >80% non-Hispanic 
Deleted:	 in the analysis was relatively limited and thus 
we cannot conclusively rule out the influence of the 
GRS in the subset of individuals ≥35 years old.
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whites and, although we were able to control for race/ethnicity, the T1D GRS needs to be 
specifically tested in other races and possibly modified according to genetic differences. 
Finally, it is possible that newly discovered variants, better capture of known HLA variants, 
stage-specific variants (e.g. progression from single to multiple autoantibody positivity) or 
longer follow-up of the cohort (allowing us to assess whether the rate of progression and 
its factors change with time) could improve the understanding of the long-term predictive 
power of the T1D GRS.  
In summary, the T1D GRS is a strong independent predictor of progression of islet 
autoimmunity and to clinical T1D in the TrialNet PTP study. Multivariate modeling 
suggests that the combination of islet autoantibody measurements, DPT-1 Risk Score, 
age and T1D GRS into a prediction model may improve assessment of T1D risk. This 
study, in addition to recent positive analyses in BABYDIAB (29)), DAISY (31) and TEDDY 
(32), suggest that future T1D prediction studies are likely to use a genetic score, such as 
the T1D GRS, at enrollment. These findings warrant further investigations on the use of 
the T1D GRS for early assessment T1D risk, particularly in longitudinal studies.  
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FIGURE LEGENDS 
Figure 1. Time to T1D in initially non-diabetic, islet autoantibody-positive relatives of 
patients, by DPT-1 Risk Score (≤7 vs. >7), number of positive autoantibodies (i.e. single 
vs multiple autoantibody positivity), and T1D GRS (<0.250 vs. ≥0.250) (P<0.0001). 
While the T1D GRS did not further increase the predictive ability in the group with DPT-
1 Risk Score >7, which already had high risk of T1D, it was able to stratify risk in 
individuals with DPT-1 Risk Score <7, with either single positive autoantibody or multiple 
positive autoantibodies. Abbreviations: DPT-1: Diabetes Prevention Trial-1. Ab+: 
autoantibody-positive. T1D: Type 1 diabetes. GRS: Genetic risk score 
 
 
Figure 2. Comparison of two-year AUC for models to predict progression to T1D in 
participants with DPT-1 Risk Scores ≤7. The clinical model (i.e., DPT-1 Risk Score, age 
and islet autoantibody number) in addition to HLA had a 2-year AUC of 0.78, compared 
to 0.82 for the clinical model in addition to GRS (p<0.0001). Abbreviations: Ab+: 
autoantibody-positive. DPT-1 Risk Score: Diabetes Prevention Trial-1 Risk Score. T1D: 
Type 1 diabetes. GRS: Genetic risk score 
 
 
Figure 3. Time to T1D in multiple islet autoantibody positive relatives, by DPT-1 Risk 
Score (≤7 vs. >7), age (<10 vs. ≥10 years) and T1D GRS (<0.250 vs. ≥0.250) 
(P=0.0001). While the T1D GRS did not further increase the predictive ability in 
24 
 
participants with DPT-1 Risk Score >7, it did stratify risk in individuals with DPT-1 Risk 
Score <7, aged <10 years or ≥10 years. Abbreviations: Ab+: autoantibody-positive. 
DPT-1 Risk Score: Diabetes Prevention Trial Risk Score. T1D: Type 1 diabetes. GRS: 
Genetic risk score 
 
 
Figure 4. Time from single to multiple islet autoantibody positivity in relatives of patients, 
by age (<35 vs. ≥35 years) and T1D GRS group (<0.295 vs. ≥0.295) (P=0.0001). While 
the T1D GRS did not further increase the predictive ability in participants aged ≥35 
years, it was able to stratify risk in individuals aged <35 years. Abbreviations: DPT-1 
Risk Score: Diabetes Prevention Trial Risk Score. MA+: Multiple autoantibody positive. 
SA+: Single autoantibody positive (confirmed). T1D: Type 1 diabetes. GRS: Genetic risk 
score 
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